Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation
| Autor: | C Raith, S. Cronin, J. Uberti, Lois Ayash, Voravit Ratanatharathorn |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male medicine.medical_specialty Transplantation Conditioning medicine.medical_treatment Hematopoietic stem cell transplantation Neutropenia Gastroenterology Carboplatin chemistry.chemical_compound Bleomycin Amifostine Testicular Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Mucositis Humans Etoposide Transplantation Chemotherapy Leukopenia Dose-Response Relationship Drug business.industry Hematopoietic Stem Cell Transplantation Hematology medicine.disease Combined Modality Therapy Surgery chemistry Kidney Diseases Germinoma medicine.symptom Cisplatin business Febrile neutropenia medicine.drug |
| Zdroj: | Bone marrow transplantation. 26(11) |
| ISSN: | 0268-3369 |
| Popis: | This report describes two patients with germ cell tumors who underwent tandem autologous peripheral stem cell transplants. The chemotherapy consisted of high-dose carboplatin and etoposide. Both patients developed chemotherapy-related toxicities, which included nephrotoxicity in one case and febrile neutropenia, thrombocytopenia, ototoxicity and mucositis in both. During the second transplant, both patients received amifostine 15 min before and 2 h after each dose of carboplatin. The patients had less mucositis and nephrotoxicity. The duration of neutropenia and thrombocytopenia was less in both cases resulting in a decreased use of antibiotics and platelet transfusions. These cases suggest that the use of amifostine may be of benefit in minimizing toxicities associated with high-dose chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|